Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLUE 
Monte Rosa Therapeutics Inc (GLUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: GLUE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.42% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 688.00M USD | Price to earnings Ratio 28.56 | 1Y Target Price 15.5 |
Price to earnings Ratio 28.56 | 1Y Target Price 15.5 | ||
Volume (30-day avg) 9 | Beta 1.54 | 52 Weeks Range 3.50 - 12.44 | Updated Date 10/27/2025 |
52 Weeks Range 3.50 - 12.44 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.58% | Operating Margin (TTM) -67.06% |
Management Effectiveness
Return on Assets (TTM) 2.66% | Return on Equity (TTM) 9.81% |
Valuation
Trailing PE 28.56 | Forward PE 10.02 | Enterprise Value 221760840 | Price to Sales(TTM) 3.87 |
Enterprise Value 221760840 | Price to Sales(TTM) 3.87 | ||
Enterprise Value to Revenue 1.25 | Enterprise Value to EBITDA 9.52 | Shares Outstanding 61759350 | Shares Floating 21117992 |
Shares Outstanding 61759350 | Shares Floating 21117992 | ||
Percent Insiders 0.73 | Percent Institutions 115.24 |
Upturn AI SWOT
Monte Rosa Therapeutics Inc
Company Overview
History and Background
Monte Rosa Therapeutics, Inc. was founded in 2018 and is headquartered in Boston, Massachusetts. It is a biotechnology company focusing on developing novel small molecule protein degraders to treat cancers and other diseases. It went public in 2021.
Core Business Areas
- Protein Degradation Therapeutics: Develops small molecule therapeutics that degrade disease-causing proteins.
- Cancer Therapeutics: Focuses on developing drugs to treat various cancers by targeting proteins critical to cancer growth and survival.
- Drug Discovery and Development: Engages in early-stage drug discovery and preclinical development activities.
Leadership and Structure
The company is led by a management team with expertise in drug discovery, development, and commercialization. The organizational structure includes research, development, and administrative functions.
Top Products and Market Share
Key Offerings
- Molecular Glue Degraders: Monte Rosa is developing a pipeline of molecular glue degraders that target previously undruggable proteins. Currently, all programs are in preclinical stages, so no market share or revenue data is yet available. Competitors include Arvinas, C4 Therapeutics, and Kymera Therapeutics.
- Preclinical Pipeline: Multiple preclinical programs are in development, but no marketed products exist. Revenue is currently derived from collaborations and partnerships. Competitors are other companies focused on protein degradation.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The protein degradation field is relatively new but rapidly growing.
Positioning
Monte Rosa Therapeutics is positioned as an innovator in the protein degradation space, focusing on developing novel small molecule degraders for difficult-to-treat diseases. Its competitive advantage lies in its platform technology and expertise in molecular glue discovery.
Total Addressable Market (TAM)
The TAM for protein degradation therapies is estimated to be significant, potentially reaching billions of dollars as more drugs are approved and adopted. Monte Rosa is positioned to capture a portion of this market with its pipeline of novel degraders.
Upturn SWOT Analysis
Strengths
- Novel technology platform for protein degradation
- Experienced management team
- Strong intellectual property position
- Partnerships with leading research institutions
Weaknesses
- Early-stage company with no approved products
- High cash burn rate
- Dependence on successful preclinical and clinical development
- Vulnerability to clinical trial failures
Opportunities
- Expanding the pipeline of protein degraders
- Securing additional partnerships and collaborations
- Advancing programs into clinical development
- Potential for breakthrough therapies in oncology and other diseases
Threats
- Competition from other protein degradation companies
- Regulatory hurdles and approval delays
- Clinical trial failures
- Market acceptance of protein degradation therapies
Competitors and Market Share
Key Competitors
- ARVN
- CTTX
- KYMR
Competitive Landscape
Monte Rosa faces competition from established pharmaceutical companies and other biotech companies focused on protein degradation. Its success depends on its ability to develop and commercialize differentiated therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expanding research programs, securing funding, and progressing through preclinical development.
Future Projections: Future growth is projected based on the success of its clinical trials and the commercial potential of its protein degrader therapies. Analyst estimates vary widely.
Recent Initiatives: Recent strategic initiatives include advancing lead programs into clinical trials, expanding partnerships, and investing in platform technology development.
Summary
Monte Rosa Therapeutics is an early-stage biotech company pioneering protein degradation therapies with a novel technology platform. Its success hinges on positive clinical trial outcomes and effective commercialization. Key challenges include high cash burn, competition, and regulatory hurdles. The company's strengths include its innovative technology and experienced management team, but it needs to mitigate risks associated with clinical development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monte Rosa Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-06-24 | President, CEO & Director Dr. Markus Warmuth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 142 | Website https://www.monterosatx.com |
Full time employees 142 | Website https://www.monterosatx.com | ||
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.